Release of cell surface HS anchored tissue factor pathway inhibitor (TFPI) [32] may have benefit in early or pre-sepsis to reduce coagulation, although the potential benefit of heparin in the later stages of sepsis may be limited due to sepsis disruption of this pathway [33]. The gene discussed is MAP3K14; the disease is Sepsis.